A pioneering clinical study will assess the safety, tolerability and effectiveness of CBD in people with Parkinson's-related psychosis.
List view / Grid view
Filter the results
Ofev, which is under review for the treatment of people with chronic fibrosing interstitial lung diseases (ILDs), has been given Breakthrough Therapy Designation.
Why has the pharma industry and its talents lost interest in developing new antibiotics?
The FDA has given the designation to niraparib for the treatment of gene-mutated castration-resistant prostate cancer.
The FDA has announced its approval of Descovy, a PrEP method therapy, to reduce the risk of HIV-1 infection from sex.
Researchers have developed a series of lipid nanoparticles, which encapsulate RNA, for effective and improved vaccine delivery.
Researchers have developed a chikungunya vaccine that can be stored at warm temperatures and manufactured quickly, which has been validated in animal models.
The FDA grants Orphan Drug Designation to treatments for rare diseases in R&D; here are the 10 most recent for oncologic conditions.
With the approval of the treatment, Rybelsus, there is a new option for treating type 2 diabetes without injections.
A new report has shown that trial evidence alone is not enough when approving new cancer drugs and that an assessment of that evidence is also needed.
Orphan Drug Designation has been given to bispecific antibody candidate, GBR 1342, for the treatment of multiple myeloma.
Cosentyx®, a treatment for an inflammatory disease has met its primary endpoints in patients during a Phase III trial.
Farxiga (dapagliflozin) has been given Fast Track designation by the FDA to reduce the risk of cardiovascular death.